Reported about 12 hours ago
Novo Nordisk is intensifying lawsuits against companies selling cheaper versions of its weight-loss drug Wegovy, yet Hims & Hers, a telehealth provider offering compounded versions, remains notably absent from these legal actions. Despite accusations from Novo regarding intellectual property violations and patient safety, Hims defends its approach to personalized medicine as a legitimate part of healthcare. Analysts question why Novo hasn't acted against Hims as it pursues legal battles with numerous smaller pharmacies and providers. This situation complicates the legal landscape surrounding drug compounding, particularly given the prior collaboration between the two companies.
Source: YAHOO